Regeneron’s Promising Phase 3 Study on Odronextamab for Follicular Lymphoma

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.

Regeneron Pharmaceuticals is conducting a Phase 3 study titled A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator’s Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1). The study aims to evaluate the safety and efficacy of odronextamab compared to rituximab combined with chemotherapy in treating follicular lymphoma, a type of non-Hodgkin lymphoma. This research is significant as it could potentially introduce a new treatment option for patients.

The intervention being tested is odronextamab, an experimental drug administered via intravenous infusion. It is designed to target specific proteins on cancer cells, potentially offering a more targeted treatment approach compared to traditional chemotherapy.

The study employs a randomized, parallel assignment model with no masking, focusing on treatment as the primary purpose. It consists of two parts: a non-randomized safety run-in and a randomized controlled trial comparing odronextamab to the current standard of care.

The study began on December 12, 2023, and is currently recruiting participants. The last update was submitted on June 24, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.

This clinical update could impact Regeneron’s stock performance and investor sentiment, especially if odronextamab proves to be a viable alternative to existing treatments. The outcome may also influence the competitive landscape in the oncology sector, where innovative therapies are highly valued.

The study is ongoing, with further details available on the ClinicalTrials portal.